This project introduces **NARWHAL**, a versatile platform and pipeline for neoantigen discovery in cancer immunotherapy. NARWHAL identifies mutated tumor-specific antigens (mTSAs) and aberrantly expressed antigens (aeTSAs) by integrating somatic mutation data, gene expression levels, and MHC binding affinity predictions. The platform’s unique k-mer profiling technique identifies aeTSAs from coding and noncoding regions, enabling comprehensive annotation. Validated with clinical data, NARWHAL advances neoantigen identification, supporting personalized cancer treatments by uncovering novel immunotherapy targets and enhancing therapeutic precision.